Advertisement

How do we treat patients with hereditary angioedema

      Abstract

      Hereditary angioedema (HAE) is due to the inherited deficiency of C1-Inhibitor (C1-Inh). When specific treatment was not available, the mortality rate for this disease was as high as 50% and the disability up to 100–150 days per year [Agostoni and Cicardi, Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71 (1992) 206]. Such a worrying scenario dramatically improves upon appropriate treatment. Nevertheless, the disease still frequently goes undiagnosed or misdiagnosed as an allergic condition. Both circumstances prevent patients from receiving drugs that could save and/or improve the quality of their life. The interest of our group for patients with HAE goes back to the early seventies [
      • Agostoni A
      • Martignoni G.C
      Hereditary angioneurotic oedema.
      ]. Since that time, 441 such patients have been examined and treated at our department; 403 are still actively followed. Here we present our experience on the treatment of HAE.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Agostoni A
        • Cicardi M
        Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients.
        Medicine (Baltimore). 1992; 71: 206-215
        • Agostoni A
        • Martignoni G.C
        Hereditary angioneurotic oedema.
        Lancet. 1973; 2: 325
        • Frank M.M
        • Sergent J.S
        • Kane M.A
        • Alling D.W
        Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study.
        N. Engl. J. Med. 1972; 286: 808-812
        • Blohme G
        Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study.
        Acta Med. Scand. 1972; 192: 293-298
        • Gelfand J.A
        • Sherins R.J
        • Alling D.W
        • Frank M.M
        Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities.
        N. Engl. J. Med. 1976; 295: 1444-1448
        • Theil P.L
        Ophthalmological examination of patients in long-term treatment with tranexamic acid.
        Acta Ophthalmol. (Copenh.). 1981; 59: 237-241
        • Endo Y
        • Nishimura S
        • Miura A
        Deep-vein thrombosis induced by tranexamic acid in idiopathic thrombocytopenic purpura.
        Jama. 1988; 259: 3561-3562
        • Woo K.S
        • Tse L.K
        • Woo J.L
        • Vallance-Owen J
        Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy.
        Br. J. Clin. Pract. 1989; 43: 465-466
        • Davies D
        • Howell D.A
        Tranexamic acid and arterial thrombosis [letter].
        Lancet. 1977; 1: 49
        • Rydin E
        • Lundberg P.O
        Letter: tranexamic acid and intracranial thrombosis.
        Lancet. 1976; 2: 49
        • Lindoff C
        • Rybo G
        • Astedt B
        Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
        Thromb. Haemost. 1993; 70: 238-240
        • Berntorp E
        • Follrud C
        • Lethagen S
        No increased risk of venous thrombosis in women taking tranexamic acid.
        Thromb. Haemost. 2001; 86: 714-715
        • Dalmau A
        • Sabate A
        • Koo M
        • Rafecas A
        • Figueras J
        • Jaurrieta E
        Prophylactic use of tranexamic acid and incidence of arterial thrombosis in liver transplantation.
        Anesth. Analg. 2001; 93: 516
        • Taparia M
        • Cordingley F.T
        • Leahy M.F
        Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia.
        Eur. J. Haematol. 2002; 68: 307-309
        • Spaulding W.B
        Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema).
        Ann. Intern. Med. 1960; 53: 739-745
        • Agostoni A
        • Cicardi M
        • Martignoni G.C
        • Bergamaschini L
        • Marasini B
        Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema.
        J. Allergy Clin. Immunol. 1980; 65: 75-79
        • Farrell G.C
        • Joshua D.E
        • Uren R.F
        • Baird P.J
        • Perkins K.W
        • Kronenberg H
        Androgen-induced hepatoma.
        Lancet. 1975; 1: 430-432
        • Johnson F.L
        • Lerner K.G
        • Siegel M
        • Feagler J.R
        • Majerus P.W
        • Hartmann J.R
        • et al.
        Association of androgenic–anabolic steroid therapy with development of hepatocellular carcinoma.
        Lancet. 1972; 2: 1273-1276
        • Kew M.C
        • Van Coller B
        • Prowse C.M
        • Skikne B
        • Wolfsdorf J.I
        • Isdale J
        • et al.
        Occurrence of primary hepatocellular cancer and peliosis hepatis after treatment with androgenic steroids.
        S. Afr. Med. J. 1976; 50: 1233-1237
        • Falk H
        • Thomas L.B
        • Popper H
        • Ishak K.G
        Hepatic angiosarcoma associated with androgenic–anabolic steroids.
        Lancet. 1979; 2: 1120-1123
        • Andriole G.L
        • Brickman C
        • Lack E.E
        • Sesterhenn I.A
        • Javadpour N
        • Linehan W.M
        • et al.
        Danazol-induced cystitis: an undescribed source of hematuria in patients with hereditary angioneurotic edema.
        J. Urol. 1986; 135: 44-46
        • Cicardi M
        • Castelli R
        • Zingale L.C
        • Agostoni A
        Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients.
        J. Allergy Clin. Immunol. 1997; 99: 194-196
        • Crampon D
        • Barnoud R
        • Durand M
        • Ponard D
        • Jacquot C
        • Sotto J.J
        • et al.
        Danazol therapy: an unusual aetiology of hepatocellular carcinoma [letter].
        J. Hepatol. 1998; 29: 1035-1036
        • Bork K
        • Harten P
        Hepatocellular adenomas in patients taking danazol for hereditary angiooedema.
        Lancet. 1999; 353: 1066-1067
        • Mantel-Teeuwisse A.K
        • Kloosterman J.M
        • Maitland-van der Zee A.H
        • Klungel O.H
        • Porsius A.J
        • de Boer A
        Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels.
        Drug Saf. 2001; 24: 443-456
        • Farkas H
        • Harmat G
        • Fust G
        • Varga L
        • Visy B
        Clinical management of hereditary angio-oedema in children.
        Pediatr. Allergy Immunol. 2002; 13: 153-161
        • Cicardi M
        • Bergamaschini L
        • Cugno M
        • Hack E
        • Agostoni G
        • Agostoni A
        Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience.
        J. Allergy Clin. Immunol. 1991; 87: 768-773
        • Pickering R.J
        • Good R.A
        • Kelly J.R
        • Gewurz H
        Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma.
        Lancet. 1969; 1: 326-330
        • Waytes A.T
        • Rosen F.S
        • Frank M.M
        Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate.
        N. Engl. J. Med. 1996; 334: 1630-1634
        • Bork K
        • Barnstedt S.E
        Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema.
        Arch. Intern. Med. 2001; 161: 714-718
        • Agostoni A
        • Bergamaschini L
        • Martignoni G
        • Cicardi M
        • Marasini B
        Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate.
        Ann. Allergy. 1980; 44: 299-301
        • Gadek J.E
        • Hosea S.W
        • Gelfand J.A
        • Santaella M
        • Wickerhauser M
        • Triantaphyllopoulos D.C
        • et al.
        Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor.
        N. Engl. J. Med. 1980; 302: 542-546
      1. Dore M, Morone G. L’angioedema ereditario. Su un raro caso di shock anafilattico da inibitore purificato di C1-esterasi. In: V Congresso Associazione Nazionale dei Medici d’Urgenza. Torino: Edizioni Minerva Medica; 1990. p. 1083–6

        • Zingale L.C
        • Pappalardo E
        • Zanichelli A
        • Agostoni A
        • Cicardi M
        C1 inhibitor concentrate: efficacy and adverse reactions.
        Int. Immunopharmacol. 2002; 318 ([abs]): 1385
        • Bork K
        • Fischer B
        • Dewald G
        Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy.
        Am. J. Med. 2003; 114: 294-298
        • Agostoni A
        • Cicardi M
        Contraindications to the use of ace inhibitors in patients with C1 esterase inhibitor deficiency.
        Am. J. Med. 1991; 90: 278
        • Cugno M
        • Nussberger J
        • Cicardi M
        • Agostoni A
        Bradykinin and the pathophysiology of angioedema.
        Int. Immunopharmacol. 2003; 3: 311-317
        • Sumino H
        • Ichikawa S
        • Ohyama Y
        • Nakamura T
        • Kanda T
        • Sakamoto H
        • et al.
        Effects of hormone replacement therapy on serum angiotensin-converting enzyme activity and plasma bradykinin in postmenopausal women according to angiotensin-converting enzyme-genotype.
        Hypertens. Res. 2003; 26: 53-58
        • Nogawa N
        • Sumino H
        • Ichikawa S
        • Kumakura H
        • Takayama Y
        • Nakamura T
        • et al.
        Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women.
        Menopause. 2001; 8: 210-215
        • Sumino H
        • Ichikawa S
        • Kanda T
        • Sakamaki T
        • Nakamura T
        • Sato K
        • et al.
        Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin.
        Am. J. Hypertens. 1999; 12: 1044-1047
        • Lansink M
        • Jong M
        • Bijsterbosch M
        • Bekkers M
        • Toet K
        • Havekes L
        • et al.
        Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice.
        Blood. 1999; 94: 1330-1336
        • Gallagher P.E
        • Li P
        • Lenhart J.R
        • Chappell M.C
        • Brosnihan K.B
        Estrogen regulation of angiotensin-converting enzyme mRNA.
        Hypertension. 1999; 33: 323-328